US 8822540
Nitisinone for treatment of oculocutaneous/ocular albinism and for increasing pigmentation
granted A61KA61K31/122A61K8/35
Quick answer
US patent 8822540 (Nitisinone for treatment of oculocutaneous/ocular albinism and for increasing pigmentation) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Aug 28 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Secretary, Department of Health and Human Services
- Grant date
- Tue Sep 02 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 28 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 15
- CPC classes
- A61K, A61K31/122, A61K8/35, A61K8/40, A61P